



TO THE NATIONAL SECURITIES MARKET COMMISSION

Madrid, 18 November 2025

OTHER RELEVANT INFORMATION

In compliance with the disclosure obligations set forth in Article 227 of Law 6/2023, of 17 March, on Securities Markets and Investment Services, and as a follow-up to the disclosure of inside information sent to the National Securities Market Commission (Comisión Nacional del Mercado de Valores) and disclosed to the market on 21 October 2025 (with official registration number 2948), Laboratorios Farmacéuticos ROVI, S.A. (hereinafter "**ROVI**" or the "**Company**") hereby announces that its subsidiary ROVI Pharma Industrial Services, S.A.U. (hereinafter "**ROIS**") has formally signed the definitive collaboration agreement with F. Hoffmann-La Roche Ltd. (hereinafter "**Roche**") for the manufacture of a new drug, currently in clinical development, belonging to Roche's metabolic and cardiovascular portfolio.

The terms of the agreement stipulate that ROIS will place a high-speed filling line at its facilities in San Sebastián de los Reyes (Madrid) available to Roche.

The estimated impact of the agreement for ROVI is a minimum increase in 2030 of between 20% and 25% in contract manufacturing business (CDMO) sales compared to sales figures for 2024.

Mr Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.

ROVI forward-looking statements

This communication contains forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that might cause the actual results, performance or achievements of ROVI, or its industrial results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The information contained in this communication represents the expectations and beliefs of ROVI as of the date hereof. ROVI wishes to state that future events or developments may cause these expectations and beliefs to change. However, while ROVI may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be considered to represent the expectations or beliefs of ROVI at any date after the date of this communication.

About ROVI

ROVI is a pan-European pharmaceutical company specialised in and dedicated to the research, development, contract manufacturing and marketing of small molecules and biological specialities. The company, which is undergoing continuous international expansion, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Poland, and has a diversified portfolio of more than 40 products, including its flagship product, bemiparin, which is available in more than 60 countries worldwide. ROVI also commercialises its internally developed enoxaparin biosimilar in Europe which is now present in approximately 60 countries. ROVI continues to develop ISM® Platform technology, a cutting-edge line of research in the field of prolonged drug release with proven advantages. For more information, visit www.rovi.es

ROVI contacts

Media:

Beatriz García

+34 662 570 818

bgarciasuarez@rovi.es

Investors:

Marta Campos

mcampos@rovi.es

Beatriz de Zavala

bdezavala@rovi.es

Victoria López-Belmonte

vlopez-belmonte@rovi.es